Targeting TLR4/PPARα-mediated neuroinflammation in the prefrontal cortex: S-ketamine and S-HNK rapidly alleviate depression-like behaviors
Quanfeng Zhu, Xiaoyue Zhou, Huangling Gao, Huili Wu, Yali Zheng
Journal of Neuroimmunology July 1, 2026 DOI: 10.1016/j.jneuroim.2026.579038 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical animal study Peer reviewed |
|---|---|
| Population | Male C57BL/6J mice |
| Interventions | S-ketamine S-hydroxynorketamine |
| Topics | Depression Esketamine Ketamine |
| Keywords | Neuroinflammation Prefrontal cortex Microglia Central nervous system |
| Key points | S-ketamine and S-hydroxynorketamine reversed depression-like behaviors, restored monoamine levels, and reduced neuroinflammation in mice by modulating the TLR4/PPARα signaling pathway. |
Abstract
Neuroinflammation, particularly Toll-like receptor 4 (TLR4)-mediated signaling, plays a critical role in the pathophysiology of depression. This study aimed to investigate the mechanisms by which S-ketamine (S-ket) and S-hydroxynorketamine (S-HNK) modulate TLR4 and peroxisome proliferator-activated receptor alpha (PPARα) signaling in the prefrontal cortex (PFC) to exert antidepressant effects. Male C57BL/6 J mice were subjected to chronic social defeat stress (CSDS) to induce depression-like behaviors. Mice received intraperitoneal administration of S-ket or S-HNK. In a subset of mice, adeno-associated virus expressing TLR4 (AAV-TLR4) or a negative control (NC) was stereotaxically injected into the medial prefrontal cortex (mPFC). Behavioral assessments included the sucrose preference test (SPT), forced swim test (FST), and social interaction test (SIT). Levels of monoaminergic neurotransmitters, including dopamine (DA), serotonin (5-hydroxytryptamine, 5-HT), and norepinephrine (NA), pro-inflammatory cytokines (interleukin (IL)-1β, IL-6, IL-8, and tumor necrosis factor-α (TNF-α)), TLR4, PPARα, indoleamine 2,3-dioxygenase 1 (IDO1), and kynurenine (Kyn) in the PFC were analyzed. CSDS induced depression-like behaviors, decreased DA, 5-HT, and NA levels in the PFC, and increased the expression of pro-inflammatory cytokines IL-1β, IL-6, IL-8, and TNF-α. Treatment with S-ket or S-HNK significantly reversed these behavioral deficits, neurotransmitter alterations, and neuroinflammatory responses. Both compounds also reduced plasma and PFC Kyn levels, upregulated PPARα expression, and downregulated TLR4 and IDO1. Notably, TLR4 overexpression partially abolished the antidepressant and anti-inflammatory effects of S-ket and S-HNK. S-ket and its metabolite S-HNK exert antidepressant effects by modulating the TLR4/PPARα signaling pathway, restoring monoaminergic neurotransmission, and attenuating neuroinflammation.
Comparable studies
Other preclinical and animal studies on esketamine for depression, most cited first.
Citations in the library
Cites 9
- Mechanisms of Ketamine Action as an Antidepressant Molecular Psychiatry March 13, 2018
- Inflammation, stress and depression: an exploration of ketamine’s therapeutic profile Drug Discovery Today February 1, 2023
- Depression treatment response to ketamine: sex-specific role of interleukin-8, but not other inflammatory markers Translational Psychiatry March 21, 2021
- A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers. Clinical Pharmacology & Therapeutics November 1, 2024
- Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study. The International Journal of Neuropsychopharmacology June 6, 2025
and 4 more in the library